We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial.
- Authors
O'Leary, Daniel H; Reuwer, Anne Q; Nissen, Steven E; Després, Jean-Pierre; Deanfield, John E; Brown, Michael W; Zhou, Rong; Zabbatino, Salvatore M; Job, Bernard; Kastelein, John J P; Visseren, Frank L J; AUDITOR investigators
- Abstract
The aim of this trial was to determine whether obese patients benefit from treatment with rimonabant in terms of progression of carotid atherosclerosis. Rimonabant, a selective cannabinoid-1 receptor blocker, reduces body weight and improves cardiometabolic risk factors in patients who are obese.
- Publication
Heart (British Cardiac Society), 2011, Vol 97, Issue 14, p1143
- ISSN
1468-201X
- Publication type
Journal Article
- DOI
10.1136/hrt.2011.223446